Current status of putative imidazoline (I1) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 10-11, 1996, Pages 845-854

  Evans, Roger G ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

2 adrenoceptors; Agents; Centrally acting antihypertensive; Hypertension; Imidazoline receptor; Kidney; Renal function; Sodium excretion

Indexed keywords

CLONIDINE; GUANABENZ; IMIDAZOLINE RECEPTOR; METHYLDOPA; MOXONIDINE; RILMENIDINE;

ANIMAL EXPERIMENT; DIURESIS; DRUG MECHANISM; DRUG RECEPTOR BINDING; FLUID BALANCE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; NATRIURESIS; NONHUMAN; RAT; REVIEW; SODIUM TRANSPORT;

EID: 0029835863     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb01132.x     Document Type: Review

References (90)

1. Head GA. Central monoamine neurons and cardiovascular control. Kidney Int. 1992; 41 (Suppl. 37): S8-13.
2. Esler MD, Lambert G, Jennings G. Increased regional sympathetic nervous activity in human hypertension: Causes and consequences. J. Hypertens. 1990; 8 (Suppl. 7): S53-7.
3. Safar ME, Weiss YA, Corval PL et al. Anti-hypertensive adrenergic-blocking agents: Effects on sodium balance, the renin-angiotensin system and haemodynamics. Clin. Sci. Mol. Med. 1975; 48; S93-5.
4. Goldberg M, Gehr M. Effects of alpha-2 agonists on renal function in hypertensive humans. J. Cardiovasc. Pharmacol. 1985; 7 (Suppl. 8): S34-7.
5. 1-imidazoline-receptor agonists in the treatment of hypertension: An appraisal of clinical experience. J. Cardiovasc. Pharmacol. 1994; 24 (Suppl. 1): S39-48.
6. 1-imidazoline receptors. J. Cardiovasc. Pharmacol. 1992; 20 (Suppl. 4): S1-10.
7. 1-imidazoline receptors in the rostral ventrolateral medulla. J. Cardiovasc. Pharmacol. 1994; 24 (Suppl. 1): S1-8.
8. Sannajust F, Head GA. Rilmenidine-induced hypotension in conscious rabbits involves imidazoline-preferring receptors. J. Cardiovasc. Pharmacol. 1994; 23: 42-50.
9. 1-Agents: A new approach to the treatment of hypertension. Ann. N.Y. Acad. Sci. 1995; 763: 642-58.
10. 1 imidazoline preferring receptors: Two unique sites mediating natriuresis in the rat. Cardiovasc. Drugs Therapy 1994; 8: 43-8.
11. Anderson WP, Evans RG, Malpas SC. Pressure natriuresis and long term blood pressure control. J. Cardiovasc. Pharmacol. 1995; 26 (Suppl. 2): S17-23.
12. Reis DJ, Regunathan S, Wang H, Feinstein DL, Meeley MP. Imidazoline receptors in the nervous system. Fund. Clin. Pharmacol. 1992; 6 (Suppl. 1): S23-9.
13. 1-imidazoline agonist. Cardiovasc. Drugs Therapy 1994; 8: 27-41.
14. 3H]-cirazoline as a tool for the characterization of imidazoline sites. Ann. N. Y. Acad. Sci. 1995; 763: 112-24.
15. 3H]-atipamezole in rat lung. A novel imidazoline binding site? Ann. N.Y. Acad. Sci. 1995; 763: 66-77.
16. 3H]imidazoline binding sites in rat kidney. Eur. J. Pharmacol. 1995; 281: 341-6.
17. 2-adrenoceptors and imidazoline binding sites: Distribution of imidazoline binding sites in rat brain. Brain Res. 1990; 514: 15-21.
18. 3H]-clonidine to identify imidazoline receptors in the rabbit brainstem. Br. J. Pharmacol. 1993; 110: 1537-43.
19. 1-imidazoline sites. J. Pharmacol. Exp. Ther. 1993; 264: 172-82.
20. 3H]clonidine. Eur. J. Pharmacol. - Mol. Pharmacol. Sect. 1994; 266: 25-33.
21. Ernsberger P, Feinland G, Meeley MP, Reis DJ. Characterization and visualization of clonidine-sensitive imidazole sites in rat kidney which recognize clonidine-displacing substance. Am. J. Hypertens. 1990; 3: 90-7.
22. Hamilton CA, Yakubu MA, Jardine E, Reid JL. Imidazole binding sites in rabbit kidney and forebrain membranes. J. Autonom. Pharmacol. 1991; 11: 277-83.
23. Hamilton CA, Jardine E, Reid JL. Down-regulation of imidazoline sites in rabbit kidney. Eur. J. Pharmacol. 1993; 243: 95-7.
24. 1-imidazoline sites. Ann. N.Y. Acad. Sci. 1995; 763: 163-8.
25. Greney H, Molines A, Bousquet P, Dontenwill M. Heterogeneity of imidazoline binding sites revealed by a cirazoline derivative. Eur. J. Pharmacol. 1994; 271: 533-6.
26. 3H]idazoxan label different populations of imidazoline sites on rat kidney. Eur. J. Pharmacol. 1993; 232: 79-87.
27. Piletz JE, Sletten K. Nonadrenergic imidazoline binding sites on human platelets. J. Pharmacol. Exp. Ther. 1993; 267: 1493-502.
28. Jenkinson DH, Barnard EA, Hoyer D et al. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 1995; 47: 255-66.
29. Kenakin TP, Bond RA, Bonner TI. Definition of pharmacological receptors. Pharmacol. Rev. 1992; 44: 351-62.
30. Escribá PV, Sastre M, Wang H et al. Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. Neurosci. Lett. 1994; 178: 81-4.
31. Greney H, Bennai F, Molines A, Belcourt A, Dontenwill M, Bousquet P. Isolation of a human cerebral imidazoline-specific binding protein. Eur. J. Pharmacol. 1994; 265: R1-2.
32. 3H]clonidine. Neurochem. Int. 1994; 25: 183-91.
33. Piletz JE, Chikkala DN, Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J. Pharmacol. Exp. Ther. 1995; 272: 581-7.
34. 1-imidazoline sites in bovine adrenal medullary membranes. Naunyn-Schmiedeberg's Arch. Pharmacol. 1993; 348: 70-6.
35. Felsen D, Ernsberger P, Sutaria PM et al. Identification, localization and functional analysis of imidazoline and alpha adrenergic receptors in canine prostate. J. Pharmacol. Exp. Ther. 1994; 268: 1063-71.
36. Regunathan S, Evinger MJ, Meeley MP, Reis DJ. Effects of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells. Biochem. Pharmacol. 1991; 42: 2011-18.
37. 2-imidazoline binding sites. Naunyn-Schmiedeberg's Arch. Pharmacol. 1995; 351: 507-16.
38. 2-imidazoline binding sites to inhibitory effects of imidazolines on ligand-gated ion channels. An investigation in the adrenal medulla and in neuroblastoma cells. Ann. N. Y. Acad. Sci. 1995; 763: 420-32.
39. 2 sites. Ann. N. Y. Acad. Sci. 1995; 763: 153-6.
40. 1-imidazoline receptors. Definition, characterization, distribution and transmembrane signaling. Ann. N. Y. Acad. Sci. 1995; 763: 22-42.
41. Musgrave IF, Krautwurst D, Hescheler J, Schultz G. Clonidine and cirazoline inhibit activation of nicotinic channels in PC-12 cells. Ann. N. Y. Acad. Sci. 1995; 763: 272-82.
42. 1-binding site in rat brown adipocytes. Ann. N. Y. Acad. Sci. 1995; 763: 398-404.
43. Bohmann C, Schollmeyer P, Rump LC. Effects of imidazolines on noradrenaline release in rat isolated kidney. Naunyn-Schmiedeberg's Arch. Pharmacol. 1994; 349: 118-24.
44. Ogidigben M, Chu T-C, Potter DE. Ocular actions of moxonidine: A possible role for imidazoline receptors. J. Pharmacol. Exp. Ther. 1994; 269: 897-904.
45. Meana JJ, Herrera-Marschitz, M, Goiny M. In vivo modulation of norepinephrine and glutamate release through imidazoline receptors in the rat central nervous system. Ann. N. Y. Acad. Sci. 1995; 763: 490-3.
46. Maiese K, Pek L, Berger SB, Reis DJ. Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J. Cereb. Blood Flow Metab. 1992; 12: 53-63.
47. Glavin GB, Smyth DD. Moxonidine decreases gastric secretion and gastric mucosal injury in rats. Ann. N. Y. Acad. Sci. 1995; 763: 433-5.
48. Pineda J, Ugedo L, García-Sevilla JA. Stimulatory effects of clonidine, cirazoline and rilmenidine on locus coeruleus noradrenergic neurones: Possible involvement of imidazoline-preferring receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 1993; 348: 134-40.
49. Grabie M, Nussbaum P, Goldfarb S et al. Effects of methyldopa on renal hemodynamics and tubular function. Clin. Pharmacol. Ther. 1980; 27: 522-7.
50. 2-adrenoceptor mediated vasoconstriction in dogs: Comparison of phenylephrine, clonidine and guanabenz. J. Cardiovasc. Pharmacol. 1984; 6 (Suppl. 5): S793-8.
51. Marchand GR, Willis LR, Williamson HE. Relationship of sodium retention produced by catapres to changes in renal hemodynamics (36024). Proc. Soc. Exp. Biol. Med. 1971; 138: 943-6.
52. + antiport activity in the rabbit renal proximal tubule. J. Clin. Invest. 1987; 80: 1755-62.
53. 2-adrenoceptors. Am. J. Physiol. 1990; 259: F1-8.
54. + transport and intracellular pH in renal proximal tubules. Biochim. Biophys. Acta 1990; 1024: 173-8.
55. Baum T, Shropshire AT. Studies on the centrally mediated hypotensive activity of guanabenz. Eur. J. Pharmacol. 1976; 37: 31-44.
56. 2-adrenoceptor agonist, on plasma atrial natriuretic peptide levels, haemodynamics and renal excretory function in spontaneously hypertensive and Wistar-Kyoto rats. Br. J. Pharmacol. 1989; 97: 125-32.
57. Sannajust F, Head GA. Effect of rilmenidine on baroreflex control of renal sympathetic nerve activity. J. Hypertens. 1993; 11 (Suppl. 5): S328-9.
58. 2-adrenoceptors. Br. J. Pharmacol. 1995; 116: 1557-70.
59. Miller M. Clonidine-induced diuresis in the rat: Evidence for a renal site of action. J. Pharmacol. Exp. Ther. 1980; 214: 608-13.
60. Roman RJ, Cowley AW, Lechene C. Water diuretic and natriuretic effect of clonidine in the rat. J. Pharmacol. Exp. Ther. 1979; 211: 385-93.
61. Blandford DE, Smyth DD. Role of vasopressin in response to intrarenal infusions of alpha-2 adrenoceptor agonists. J. Pharmacol. Exp. Ther. 1990; 255: 264-70.
62. Blandford DE, Smyth DD. Enhanced natriuretic potency of intravenous clonidine: Extrarenal site of action? Eur. J. Pharmacol. 1989; 174: 181-8.
63. Zeigler DW, Adajar RV, Patel KP. Role of renal nerves in natriuresis and diuresis produced by centrally administered clonidine. FASEB J. 1988; 2: A1319 (Abstract).
64. Kline RL, Mercer PF. Contribution of renal nerves to the natriuretic and diuretic effect of alpha-2 adrenergic receptor activation. J. Pharmacol. Exp. Ther. 1990; 253: 266-71.
65. Kline RL, Cechetto DF. Renal effects of rilmenidine in anesthetized rats: Importance of renal nerves. J. Pharmacol. Exp. Ther. 1993; 266: 1556-62.
66. 1 imidazoline agonist, moxonidine. Br. J. Pharmacol. 1995; 116: 2631-6.
67. Hesse IFA, Johns EJ. The role of α-adrenoceptors in the regulation of renal tubular sodium reabsorption and renin secretion in the rabbit. Br. J. Pharmacol. 1985; 84: 715-24.
68. Chrysanthakopoulos SG, Lavender AR. Water diuresis from clonidine (catapres) (38979). Proc. Soc. Exp. Biol. Med. 1975; 150: 85-91.
69. Strandhoy JW, Morris M, Steg BD, Buckalew VM Jr. Synergistic effect of modest volume expansion on the diuretic and natriuretic action of guanabenz. J. Pharmacol. Exp. Ther. 1983; 226: 419-24.
70. Olsen UB. Clonidine-induced increase of renal prostaglandin activity and water diuresis in conscious dogs. Eur. J. Pharmacol. 1976; 36: 95-101.
71. Onesti G, Schwartz AB, Kim KE, Paz-Martinez V, Swartz C. Antihypertensive effect of clonidine. Circ. Res. 1971; 28 & 29 (Suppl. II): 153-69.
72. Blandford DE, Smyth DD. Dose selective dissociation of water and solute excretion after renal alpha-2 adrenoceptor stimulation. J. Pharmacol. Exp. Ther. 1988; 247: 1181-6.
73. 1-imidazoline receptor agonist? Ann. N. Y. Acad. Sci. 1995; 763: 96-9.
74. Smyth DD, Li P, Blandford DE, Penner SB. Opposite rank order of potency for alpha-2 adrenoceptor agonists on water and solute excretion in the rat: Two sites and/or receptors? J. Pharmacol. Exp. Ther. 1992; 261: 1080-6.
75. Li P, Smyth DD. Suppressed renal response to 2,6-dimethyl clonidine but not clonidine in one kidney-one clip hypertensive rats. J. Pharmacol. Exp. Ther. 1993; 267: 1395-400.
76. Allan DR, Penner SB, Smyth DD. Renal imidazoline preferring sites and solute excretion in the rat. Br. J. Pharmacol. 1993; 108: 870-5.
77. Penner SB, Smyth DD. Rilmenidine alters renal function when administered intracerebroventricularly or intrarenally. Ann. N. Y. Acad. Sci. 1995; 763: 353-6.
78. Smyth DD, Darkwa FK, Penner SB. Imidazoline receptors and sodium excretion in the rat kidney Ann. N. Y. Acad. Sci. 1995; 763: 340-52.
79. 1 imidazoline receptor agonist, moxonidine. Br. J. Pharmacol. 1994; 112: 1089-94.
80. Evans RG, Shweta A, Malpas SC et al. Renal effects of rilmenidine in anaesthetised volume loaded dogs. Clin. Exp. Pharmacol. Physiol. 1996 (in press).
81. 3H]-rauwolscine in the kidney of the dog. Clin. Exp. Pharmacol. Physiol. 1994; 21: 649-58.
82. Mohammed S, Hanenson IB, Magenheim HG, Gaffney TE. The effects of alpha-methyldopa on renal function in hypertensive patients. Am. Heart J. 1968; 76: 21-7.
83. Bosanac P, Dubb J, Walker B, Goldberg M, Agus ZS. Renal effects of guanabenz: A new antihypertensive. J. Clin. Pharmacol. 1976; 16: 631-6.
84. Gehr M, MacCarthy EP, Goldberg M. Guanabenz: A centrally acting, natriuretic antihypertensive drug. Kidney Int. 1986; 29: 1203-8.
85. Campese VM, Romoff M, Telfer N, Weidmann P, Massry SG. Role of sympathetic nerve inhibition and body sodium-volume state in the antihypertensive action of clonidine in essential hypertension. Kidney Int. 1980; 18: 351-7.
86. Bauer JH Effects of guanabenz therapy on renal function and body fluid composition. Arch. Intern. Med. 1983; 143: 1163-7.
87. Leary WP. Renal excretory actions of antihypertensive agents. Effects of rilmenidine. Am. J. Med. 1989; 87 (Suppl. 3C): S63-6.
88. Wiecek A, Fliser D, Nowicki M, Ritz E. Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man. Eur. J. Clin. Pharmacol. 1995; 48: 203-8.
89. Dallocchio M, Gosse P, Fillastre JP et al. La rilmenidine, un nouvel antihypertenseur dans le traitment de première intention de l'hypertension artérielle essentielle. Etude multicentrique en double aveugle contre aténolol. Presse Medicale 1991; 20: 1265-72.
90. United Kingdom Working Party on Rilmenidine. Rilmenidine in mild to moderate essential hypertension. Curr. Ther. Res. 1990; 47: 194-221.